Show Notes
One of the most common questions we get asked in the LiverHealthPod is what about Creatine? In this episode Paul, John and Will - three liver doctors with over 60 years of collective experience in managing liver disease discuss their opinion of Creatine. If you want to hear the evidence tune into this episode of the LiverHealthPOD Send us an email at [email protected]
More from LiverHealthPOD
In this episode of the LiverHealthPOD Paul, John and Will discuss detection of liver fibrosis in the community. Most people with significant liver scarring have no idea it's happening. No pain, no jaundice, no obvious symptoms — until the disease has already progressed to cirrhosis. In this episode, we explore why detecting liver fibrosis earlier — and closer to home — is one of the most important frontiers in liver health today, and what a painless, non-invasive scan is revealing about the hidden burden of liver disease in our communities.
In this episode of the LiverHealthPOD John, Will and Paul discuss new developments in Hepatitis B. Hepatitis B affects over 300 million people worldwide and remains the leading cause of liver cancer globally — yet for decades, treatment options have been limited to viral suppression rather than cure. In this episode we break down the exciting wave of new therapies that are changing what's possible for people living with chronic hepatitis B. If you like the Podcast don't forget to like and subscribe and send us an email with your stories to LiverHealthPOD.
"The 'D' in MASLD — Does It Belong?" Everyone's talking about MASLD — but are we all agreeing on what it actually is? In this episode, we dive deep into one of hepatology's most hotly debated questions: does metabolic dysfunction-associated steatotic liver disease truly qualify as a disease, or is it a spectrum, a risk factor, or simply a label we've slapped on a very complicated process? We unpack the very real clinical consequences of how we define this condition. Whether you're a clinician, a researcher, or someone navigating a MASLD diagnosis yourself, this one will challenge how you think about the liver — and the language we use to talk about it. 🎙️ Got a question or a hot take? We want to hear from you for our Mailbag Segment! Send your thoughts, questions, and controversial opinions to [email protected] and you might just hear yourself featured on the next episode. Subscribe, rate, and share liverHealthPOD — because your liver deserves the conversation.
In this episode ,Will, Paul and John discuss medications for Alcohol use disorder (AUD) . In this episode, we unpack the evidence-based pharmacotherapies that support recovery, including Naltrexone, Acamprosate, and Disulfiram and more. This is a practical, stigma-aware conversation focused on improving outcomes—because effective treatment for alcohol use disorder should be accessible and evidence-based. Don't forget to leave a rating so others can find us and send any questions to [email protected]
In this episode of the LiverHealthPOD John, Will and Paul discuss "Lean MAFLD". These patients may not fit the typical metabolic stereotype, but they can still progress to fibrosis and cirrhosis. which challenges the outdated assumption that fatty liver disease is simply a consequence of obesity. People with a “normal” BMI can still develop significant hepatic steatosis and inflammation, often driven by a combination of genetic susceptibility, visceral adiposity, insulin resistance, and environmental factors. Find out more in this episode. Don't forget to leave us a 5 star rating and send us a message of questions to [email protected]